Jack A. Khattar is President, CEO of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 926,172 shares of SUPN, which is worth approximately $33.5 Million. The most recent transaction as insider was on Jan 18, 2023, when has been sold 4,936 shares (Common Stock) at a price of $40.4 per share, resulting in proceeds of $199,414. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 926K
1.2% 3M change
6.77% 12M change
Total Value Held $33.5 Million

Jack A. Khattar Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 18 2023
SELL
Open market or private sale
$199,414 $40.4 p/Share
4,936 Reduced 0.62%
794,317 Common Stock
Jan 18 2023
BUY
Exercise of conversion of derivative security
$77,244 $9.56 p/Share
8,080 Added 1.0%
799,253 Common Stock
Jan 17 2023
SELL
Open market or private sale
$1,018,603 $40.03 p/Share
25,446 Reduced 3.12%
791,173 Common Stock
Jan 17 2023
BUY
Exercise of conversion of derivative security
$400,755 $9.56 p/Share
41,920 Added 4.88%
816,619 Common Stock
Dec 21 2022
SELL
Open market or private sale
$433,041 $38.14 p/Share
11,354 Reduced 1.37%
814,699 Common Stock
Dec 21 2022
BUY
Grant, award, or other acquisition
-
15,625 Added 1.9%
807,581 Common Stock
Dec 21 2022
BUY
Exercise of conversion of derivative security
$176,592 $9.56 p/Share
18,472 Added 2.19%
826,053 Common Stock
Dec 20 2022
SELL
Open market or private sale
$152,308 $38.02 p/Share
4,006 Reduced 0.5%
791,956 Common Stock
Dec 20 2022
BUY
Exercise of conversion of derivative security
$62,407 $9.56 p/Share
6,528 Added 0.81%
795,962 Common Stock
Nov 25 2022
SELL
Open market or private sale
$391,729 $35.18 p/Share
11,135 Reduced 1.39%
789,434 Common Stock
Nov 25 2022
BUY
Exercise of conversion of derivative security
$170,110 $9.56 p/Share
17,794 Added 2.17%
800,569 Common Stock
Nov 23 2022
SELL
Open market or private sale
$79,177 $35.05 p/Share
2,259 Reduced 0.29%
782,775 Common Stock
Nov 23 2022
BUY
Exercise of conversion of derivative security
$34,568 $9.56 p/Share
3,616 Added 0.46%
785,034 Common Stock
Nov 22 2022
SELL
Open market or private sale
$21,000 $35.0 p/Share
600 Reduced 0.08%
781,418 Common Stock
Nov 22 2022
BUY
Exercise of conversion of derivative security
$9,168 $9.56 p/Share
959 Added 0.12%
782,018 Common Stock
Nov 21 2022
SELL
Open market or private sale
$18,590 $35.01 p/Share
531 Reduced 0.07%
781,059 Common Stock
Nov 21 2022
BUY
Exercise of conversion of derivative security
$8,106 $9.56 p/Share
848 Added 0.11%
781,590 Common Stock
Nov 15 2022
SELL
Open market or private sale
$39,025 $35.0 p/Share
1,115 Reduced 0.14%
780,742 Common Stock
Nov 15 2022
BUY
Exercise of conversion of derivative security
$17,045 $9.56 p/Share
1,783 Added 0.23%
781,857 Common Stock
Sep 14 2022
SELL
Exercise of conversion of derivative security
$46,575 $33.75 p/Share
1,380 Reduced 0.18%
780,074 Common Stock
Sep 14 2022
BUY
Exercise of conversion of derivative security
-
5,895 Added 0.75%
781,454 Common Stock
Aug 16 2022
SELL
Exercise of conversion of derivative security
$312,280 $34.01 p/Share
9,182 Reduced 1.15%
790,249 Common Stock
Aug 16 2022
SELL
Open market or private sale
$499,607 $34.01 p/Share
14,690 Reduced 1.86%
775,559 Common Stock
Aug 16 2022
BUY
Exercise of conversion of derivative security
-
39,530 Added 4.71%
799,431 Common Stock
Aug 15 2022
SELL
Exercise of conversion of derivative security
$367,966 $34.03 p/Share
10,813 Reduced 1.37%
777,203 Common Stock

Also insider at

SCPH
scPharmaceuticals Inc. Healthcare
CGTX
COGNITION THERAPEUTICS INC Healthcare
JAK

Jack A. Khattar

President, CEO
Rockville, MD

Track Institutional and Insider Activities on SUPN

Follow SUPERNUS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN